Risk Assessment, Genetic Counseling, and Genetic Testing for<i>BRCA</i>-Related Cancer
Authors: Douglas K. Owens, Karina W. Davidson, Alex H. Krist, Michael J. Barry, Michael Cabana, Aaron B. Caughey, Chyke A. Doubeni, John W. Epling, Martha Kubik, C. Seth Landefeld, Carol M. Mangione, Lori Pbert, Michael Silverstein, Melissa A. Simon, Chien-Wen Tseng, John B. Wong
Journal: JAMA (2019)

<h3>Importance</h3> Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (<i>BRCA1/2</i>) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death. In the general population,<i>BRCA1/2</i>mutations occur in an estimated 1 in 300 to 500 women and account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases. <h3>Objective</h3> To update the 2013 US Preventive Services Task Force (USPSTF) recommendation on risk assessment, genetic counseling, and genetic testing for<i>BRCA</i>-related cancer. <h3>Evidence Review</h3> The USPSTF reviewed the evidence on risk assessment, genetic counseling, and genetic testing for potentially harmful<i>BRCA1/2</i>mutations in asymptomatic women who have never been diagnosed with<i>BRCA</i>-related cancer, as well as those with a previous diagnosis of breast, ovarian, tubal, or peritoneal cancer who have completed treatment and are considered cancer free. In addition, the USPSTF reviewed interventions to reduce the risk for breast, ovarian, tubal, or peritoneal cancer in women with potentially harmful<i>BRCA1/2</i>mutations, including intensive cancer screening, medications, and risk-reducing surgery. <h3>Findings</h3> For women whose family or personal history is associated with an increased risk for harmful mutations in the<i>BRCA1/2</i>genes, or who have an ancestry associated with<i>BRCA1/2</i>gene mutations, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are moderate. For women whose personal or family history or ancestry is not associated with an increased risk for harmful mutations in the<i>BRCA1/2</i>genes, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are small to none. Regardless of family or personal history, the USPSTF found adequate evidence that the overall harms of risk assessment, genetic counseling, genetic testing, and interventions are small to moderate. <h3>Conclusions and Recommendation</h3> The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with<i>BRCA1/2</i>gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing. (B recommendation) The USPSTF recommends against routine risk assessment, genetic counseling, or genetic testing for women whose personal or family history or ancestry is not associated with potentially harmful<i>BRCA1/2</i>gene mutations. (D recommendation)